Compare Ginkgo Bioworks Holdings Inc (DNA) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs EPAM Systems Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.15 (market cap $590.53M), while EPAM Systems Inc trades at $87.74 (market cap $4.41B). The key difference: EPAM Systems Inc is far larger — about 7.5× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.
| DNA | EPAM | |
|---|---|---|
Market Cap | $590.53M | $4.41B |
Sector | Health | Technology |
52-Week High | $16.14 | $221.40 |
52-Week Low | $5.48 | $76.04 |
Enterprise Value | $627.78M | $3.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
EPAM trades at $86.38, up 2.97% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows attractive valuation with a P/E of 12.41 and P/S of 0.86, supported by consistent earnings beats in recent quarters. Revenue grew to $5.46B in 2025, though net income margin dipped to 6.96%. Recent news highlights EPAM's AI partnerships and upcoming Q2 earnings, with analyst sentiment strongly bullish.
The outlook for EPAM is positive given its low valuation multiples and strong analyst consensus, with a price target of $128.55 implying significant upside. Risks include competitive pressures in IT services and potential margin compression, but the company's focus on AI transformation and solid cash flow generation provide a foundation for growth. Investors should weigh the high institutional confidence against macroeconomic headwinds affecting the tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
